2 min read
Stay updated with the latest - Click here to follow us on Instagram
Journalism of Courage
Premium
This is an archive article published on December 7, 2020
Bharat Biotech seeks emergency use authorisation for indigenously developed Covaxin
The applications of Bharat Biotech, Serum Institute of India and Pfizer will be reviewed by the subject expert committee on COVID-19 at the Central Drugs Standard Control Organisation on Wednesday, sources said.
Representational Image (File)After Pfizer and Serum Institute, Hyderabad-based pharmaceutical firm Bharat Biotech on Monday applied to the central drug regulator seeking emergency use authorisation for its COVID-19 vaccine Covaxin, official sources said.
The applications of Bharat Biotech, Serum Institute of India and Pfizer will be reviewed by the subject expert committee (SEC) on COVID-19 at the Central Drugs Standard Control Organisation (CDSCO) on Wednesday, sources said.
COVID vaccine: CDSCO expert panel to review on Wednesday applications of Pfizer, Serum Institute of India and Bharat Biotech, say sources
— Press Trust of India (@PTI_News) December 7, 2020
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
On December 4, Prime Minister Narendra Modi at an all-party meeting had expressed hope that a COVID-19 vaccine may be ready in a few weeks.
That same evening, the Indian arm of US pharmaceutical giant Pfizer sought emergency use approval for its vaccine from the central drug regulator, after the firm secured such clearance in the UK and Bahrain.
The Serum Institute sought such nod for the Oxford COVID-19 vaccine, Covishield, on December 6.
Advertisement
Loading Taboola...
Live Blog
Top Stories
Advertisement